Marker Therapeutics, Inc. — fact timeline

Marker Therapeutics, Inc. shareholders approved Adjournment of Annual Meeting if necessary to solicit additional votes on Proposal 3 at the 2026-05-01 meeting.

“Proposal No. 6 : Approval of the adjournment of the Annual Meeting in the event that the number of shares of Common Stock present or represented by proxy at the Annual Meeting and voting "FOR" the adoption of Proposal 3 is insufficient. The votes were cast as follows: Votes For Votes Against Abstained Adjournment 11,264,545 1,003,337 109,974 Broker Non-Votes: 0.”

Marker Therapeutics, Inc. shareholders approved Ratification of CBIZ as independent auditor for fiscal year 2026 at the 2026-05-01 meeting.

“Proposal No. 5 : Ratification of the selection by the Audit Committee of the Board of Directors of CBIZ CPAs P.C. ("CBIZ") as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2026. The votes were cast as follows: Votes For Votes Against Abstained Ratification of appointment of CBIZ 11,626,068 1,003,337 109,974 Broker Non-Votes: 0.”

Marker Therapeutics, Inc. shareholders rejected Approval of Charter Amendment to revise voting threshold for increase or decrease of Common Stock at the 2026-05-01 meeting.

“Proposal No. 4: Approval of the adoption of an amendment to our Certificate of Incorporation, as amended, to revise the voting threshold required for an increase or decrease of Common Stock. The votes were cast as follows: Votes For Votes Against Abstained Approval of Charter Amendment to Revise Voting Threshold 8,279,190 1,222,558 71,209 Broker Non-Votes: 2,804,902.”

Marker Therapeutics, Inc. shareholders approved Approval of Charter Amendment to increase authorized shares from 30,000,000 to 130,000,000 at the 2026-05-01 meeting.

“Proposal No. 3: Approval of the adoption of an amendment to our Certificate of Incorporation, as amended, to increase the number of authorized shares of our Common Stock from 30,000,000 shares of Common Stock to 130,000,000 shares of Common Stock. The votes were cast as follows: Votes For Votes Against Abstained Approval of Charter Amendment to Increase Authorized Common Stock. 10,851,228 1,412,017 114,611 Broker Non-Votes: 0.”

Marker Therapeutics, Inc. shareholders approved Advisory approval of named executive officer compensation at the 2026-05-01 meeting.

“Proposal No. 2 : Approval, on an advisory basis, of the compensation of the Company’s named executive officers. The votes were cast as follows: Votes For Votes Against Abstained Advisory approval of named executive officer compensation 8,548,905 471,261 552,789 Broker Non-Votes: 2,804,902.”

Marker Therapeutics, Inc. shareholders approved Election of five nominees to serve as directors at the 2026-05-01 meeting.

“Proposal No. 1 : Election of five nominees to serve as directors until the 2027 annual meeting of stockholders and until their respective successors are elected and qualified. The votes were cast as follows: Name Votes For Votes Withheld David Eansor 9,297,478 275,480 Steven Elms 9,347,549 225,409 Katharine Knobil 9,314,762 258,196 Juan Vera 9,331,093 241,865 Kathryn Penkus Corzo 9,377,143 195,815 Broker Non-Votes: 2,804,902.”

Marker Therapeutics, Inc.: Amendment to increase authorized common stock from 30,000,000 to 130,000,000 shares (effective 2026-05-01).

“the Company’s stockholders approved an amendment to the Company’s Certificate of Incorporation, as amended, to increase the number of authorized shares of our Common Stock from 30,000,000 shares of Common Stock to 130,000,000 shares of Common Stock (the “ Charter Amendment ”).”

Marker Therapeutics, Inc. reported the year ended December 31, 2025 results: net income $12.2 million.

“Marker reported a net loss of $12.2 million for the year ended December 31, 2025”

Marker Therapeutics, Inc. engaged CBIZ CPAs P.C. as its auditor.

“CBIZ CPAs was engaged to serve as the independent registered public accounting firm of the Company for the year ending December 31, 2025”

Marcum LLP resigned as auditor of Marker Therapeutics, Inc..

“On August 6, 2025, Marcum resigned as the Company’s independent registered public accounting firm and CBIZ CPAs was engaged to serve as the independent registered public accounting firm of the Company for the year ending December 31, 2025”

John Wilson resigned as Director at Marker Therapeutics, Inc..

“On January 24, 2025, Mr. John Wilson resigned from the Board of Directors of Marker Therapeutics, Inc.”

Marker Therapeutics, Inc. reported financial results for first quarter ended March 31, 2024.

“Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumors, today reported corporate updates and financial results for the first quarter ended March 31, 2024.”

Marker Therapeutics, Inc. reported financial results for the fiscal year ended December 31, 2023.

“On March 25, 2024, Marker Therapeutics, Inc. (the “ Company ”) reported financial results for the fiscal year ended December 31, 2023 and other recent corporate updates.”

Marker Therapeutics, Inc. terminated Purchase Agreement with Lincoln Park Capital Fund, LLC (effective 2024-03-01).

“On February 29, 2024, Marker Therapeutics, Inc. (the “Company”) delivered notice to Lincoln Park Capital Fund, LLC, an Illinois limited liability company (“LPC”), terminating the Purchase Agreement, dated December 12, 2022 (the “Purchase Agreement”), with LPC effective March 1, 2024”

Marker Therapeutics, Inc. entered into Master Services Agreement for Product Supply with Cell Ready LLC valued at $750,000 (effective 2024-02-22).

“(the “Company”) entered into a Master Services Agreement for Product Supply (the “Agreement”) with Cell Ready LLC (“Cell Ready”).”

Juan Vera was appointed as Principal Financial and Accounting Officer at Marker Therapeutics, Inc..

“Juan Vera, the Company’s President and Chief Executive Officer, was appointed as the Company’s Principal Financial and Accounting Officer.”

Eliot M. Lurier departed as Interim Chief Financial Officer and Principal Financial and Accounting Officer at Marker Therapeutics, Inc..

“On November 17, 2023, Mr. Lurier ceased serving as the Company’s Interim Chief Financial Officer and Principal Financial and Accounting Officer”

Marker Therapeutics, Inc. reported the third quarter ended September 30, 2023 results: net income ($3.0) million.

“Marker reported a net loss of ($3.0) million for the quarter ended September 30, 2023, compared to a net loss of ($6.9) million, inclusive of the $(1.2) million loss from discontinued operations, reflected in the quarter ended September 30, 2022.”

Marker Therapeutics, Inc. reported financial results for the second quarter ended June 30, 2023.

“Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today reported corporate updates and financial results for the second quarter ended June 30, 2023.”

Eliot M. Lurier was appointed as Interim Chief Financial Officer at Marker Therapeutics, Inc..

“the Company appointed Eliot M. Lurier as the Company’s Interim Chief Financial Officer.”

Michael Loiacono departed as Chief Accounting Officer at Marker Therapeutics, Inc..

“Michael Loiacono, the Chief Accounting Officer of Marker Therapeutics, Inc. (the “ Company ”), was separated from the Company.”

Marker Therapeutics, Inc. completed a disposition involving Cell Ready, LLC for approximately $19.0 million (closed 2023-06-26).

“Company completed the disposition of the Purchased Assets to Cell Ready pursuant to the Transaction. The aggregate consideration paid for the Purchased Assets was approximately $19.0 million. In connection with the Transaction, Cell Ready plans to make offers of employment to approximately 50 of the Company's employees currently employed in its manufacturing,”

Marker Therapeutics, Inc. shareholders approved Ratification of the selection of Marcum LLP as independent registered public accounting firm for the fiscal year ending December 31, 2023. at the 2023-06-06 meeting.

“Proposal No. 4 : Ratification of the selection of Marcum LLP as independent registered public accounting firm for the fiscal year ending December 31, 2023. The votes were cast as follows: Votes For Votes Against Abstained Ratification of appointment of Marcum LLP 5,760,786 109,958 19,128 Broker Non-Votes: 0.”

Marker Therapeutics, Inc. shareholders approved Indication, on an advisory basis, of the preferred frequency of future shareholder advisory votes on the compensation of the Company’s named executive officers. at the 2023-06-06 meeting.

“Proposal No. 3 : Indication, on an advisory basis, of the preferred frequency of future shareholder advisory votes on the compensation of the Company’s named executive officers. The votes were cast as follows: One Year Two Years Three Years Abstained Advisory indication of preferred frequency of future shareholder advisory votes on named executive officer compensation 2,535,976 25,098 102,082 33,619 Broker Non-Votes: 3,193,097.”

Marker Therapeutics, Inc. shareholders approved Approval, on an advisory basis, of the compensation of the Company’s named executive officers. at the 2023-06-06 meeting.

“Proposal No. 2 : Approval, on an advisory basis, of the compensation of the Company’s named executive officers. The votes were cast as follows: Votes For Votes Against Abstained Advisory approval of named executive officer compensation 2,347,263 321,791 27,721 Broker Non-Votes: 3,193,097.”

Marker Therapeutics, Inc. shareholders approved Election of five nominees to serve as directors until the 2023 annual meeting of stockholders and until their respective successors are elected and qualified. at the 2023-06-06 meeting.

“Proposal No. 1 : Election of five nominees to serve as directors until the 2023 annual meeting of stockholders and until their respective successors are elected and qualified. The votes were cast as follows: Name Votes For Votes Withheld David Eansor 2,488,644 208,131 Steven Elms 2,500,415 196,360 John Wilson 2,473,599 223,176 Juan Vera 2,499,068 197,707 Katharine Knobil 2,495,539 201,236 Broker Non-Votes: 3,193,097.”

Marker Therapeutics, Inc. entered into Purchase Agreement with Cell Ready, LLC valued at approximately $19.0 million (effective 2023-05-01).

“On May 1, 2023, Marker Therapeutics, Inc. (the “ Company ”) entered into a purchase agreement (the “ Agreement ) with Cell Ready, LLC (“ Cell Ready ”), pursuant to which the Company will (i) assign to Cell Ready the leases for the Company's two manufacturing facilities in Houston, Texas (the “ Manufacturing Facilities ”), (ii) sell to Cell Ready all of the equipment and leasehold improvements at the Manufacturing Facilities and (iii) assign to Cell Ready its rights, title and interest in the Company's Master Services Agreement for Product Supply, dated April 7, 2023, by and between the Company, Cell Ready and Indapta Therapeutics, Inc., as well as its rights, title and interest in any contracts related to the equipment and Manufacturing Facilities (collectively, the “ Purchased Assets ”). Pursuant to the Agreement, Cell Ready will acquire the Purchased Assets for total consideration of approximately $19.0 million. In connection with the purchase of the Manufacturing Facilities, Cell Re”

David Laskow-Pooley departed as Director at Marker Therapeutics, Inc..

“On April 27, 2023, Mr. David Laskow-Pooley, a member of the Board, notified the Board that he will not stand for reelection as a director of the Company upon expiration of his current term.”

Juan Vera was appointed as President and Chief Executive Officer at Marker Therapeutics, Inc..

“On April 27, 2023, the Board appointed Juan Vera as the Company’s President and Chief Executive Officer, effective as of the effective time of Mr. Hoang’s resignation.”

Peter Hoang resigned as Director at Marker Therapeutics, Inc..

“Mr. Hoang also resigned as a member of the Company’s Board of Directors (the “ Board ”), effective immediately.”

Peter Hoang resigned as President and Chief Executive Officer at Marker Therapeutics, Inc..

“On April 27, 2023, Peter Hoang, the Company’s President and Chief Executive Officer, resigned from his operating role, effective May 1, 2023.”

Mythili Koneru resigned as Chief Medical Officer at Marker Therapeutics, Inc..

“On March 13, 2023, Mythili Koneru, Chief Medical Officer of Marker Therapeutics, Inc. (the “ Company ”), notified the Company of her intent to resign as Chief Medical Officer of the Company effective as of April 9, 2023.”

Marker Therapeutics, Inc. entered into Registration Rights Agreement with Lincoln Park Capital Fund, LLC (effective 2022-12-12).

“Concurrently with entering into the Purchase Agreement, we also entered into a registration rights agreement with Lincoln Park, or the Registration Rights Agreement, pursuant to which we agreed to register the sale of the shares of our common stock that have been and may be issued to Lincoln Park under the Purchase Agreement pursuant to a Registration Statement on Form S-1, or the Registration Statement.”

Marker Therapeutics, Inc. entered into Purchase Agreement with Lincoln Park Capital Fund, LLC valued at up to $25,000,000 of shares of our common stock (effective 2022-12-12).

“On December 12, 2022, Marker Therapeutics, Inc., a Delaware corporation referred to herein as we, us, our or the Company, entered into a purchase agreement, or the Purchase Agreement, with Lincoln Park Capital Fund, LLC, or Lincoln Park, which provides that, upon the terms and subject to the conditions and limitations set forth therein, we have the right, but not the obligation, to sell to Lincoln Park up to $25,000,000 of shares of our common stock, or the Purchase Shares, from time to time over the 24-month term beginning on the Commencement Date (as defined below).”

Marker Therapeutics, Inc. reported the quarter ended September 30, 2022 results: net income $6.9 million.

“Marker reported a net loss of $6.9 million for the quarter ended September 30, 2022, compared to a net loss of $12.4 million for the quarter ended September 30, 2021.”

Anthony Kim departed as Chief Financial Officer at Marker Therapeutics, Inc..

“Marker Therapeutics, Inc. (the “ Company ”) previously announced that the Company had separated Anthony Kim, Chief Financial Officer of the Company, effective September 30, 2022, as part of the Company’s capital conservation measures.”

Frederick Wasserman departed as Chair of the Board at Marker Therapeutics, Inc..

“On April 5, 2022, Mr. Frederick Wasserman, a member of the board of directors (the “Board”) of Marker Therapeutics, Inc. (the “Company”), notified the Board that he will not stand for reelection as a director of the Company upon expiration of his current term.”

Katharine Knobil was appointed as Director at Marker Therapeutics, Inc..

“Effective December 8, 2021, the Board of Directors (the “ Board ”) of Marker Therapeutics, Inc. (the “ Company ”) appointed Katharine Knobil, M.D. as a member of the Board”

Juan Vera was appointed as Chief Scientific Officer and Chief Operating Officer at Marker Therapeutics, Inc..

“On November 10, 2021, the Board of Directors (the “ Board ”) of Marker Therapeutics, Inc. (the “ Company ”) appointed Juan Vera, M.D., the Company’s then-current Chief Development Officer, to serve as the Company’s Chief Scientific Officer and Chief Operating Officer, effective as of November 12, 2021.”